Srinivas Rao

Q4 #Earnings update: Strong financial position following a successful capital raise, with two Phase 2 trials underway & large Phase 2b results expected mid-2025. We enter 2025 in a position of strength, focused on transforming #mentalhealth. bit.ly/4ioeENc

The first patient has been dosed in Elumina, our Ph2 trial of VLS-01 for TRD – an important milestone. With ~100M people affected and limited options, we focus on conditions with high unmet need. Looking forward to the data in Q1’26. ir.atai.life/news-release...

Milestone update: Enrollment complete in Ph2b trial of Beckley Psytech’s BPL-003 for treatment-resistant depression (TRD). Results expected mid-2025. Full announcement: bit.ly/4immzun

It's so sad to read about all of the struggles that this region--where I grew up--is going through. The loss of life there is heartbreaking.

Studies show that funding from the National Institutes of Health (NIH) contributed to 354 of 356 drugs (99.4%) approved by the FDA from 2010 to 2019. Recklessly slashing NIH funding will mean that patients will be waiting much longer for life-saving treatments.

Honored to step into the role of sole CEO at atai. Thanks to @flobrand.bsky.social for his visionary leadership that brought atai to where it is today. Thrilled to build on this foundation with a strengthened leadership team. Full press release: ir.atai.life/news-release...

@drobrienmd.bsky.social

Great to see a pharmacotherapy get approved for OSA, a huge unmet medical need! This takes me back to my Cypress Bio days, where we tested a centrally acting agent in this indication in a phase 2 trial. While the trial was negative, we learned a great deal about OSA variability.

Vertex touts pain drug results, but medicine does not outperform placebo in sciatica study A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.

This is an important biotech result - and a disappointing one.

There's a desperate need for effective pain treatments that could be an alternative to opioids.

Vertex has been developing a promising one. But in a mid-stage study, it did no better than placebo.

www.statnews.com/2024/12/19/v...

(PDF) Psilocybin increases emotional empathy in patients with major depression PDF | Empathy plays a crucial role in interpersonal relationships and mental health. It is decreased in a variety of psychiatric disorders including... | Find, read and cite all the research you need ...

Psilocybin increases emotional empathy in patients with major depression
www.researchgate.net/publication/...

Congratulations to the Beckley Psytech team on the promising Phase 2a proof-of-concept results for ELE-101. The safety and efficacy signals are encouraging. We're proud to support Beckley Psytech as we continue our mission to develop scalable interventional psychiatry treatments for depression.

A Pragmatic Approach to Psychedelic Drug Development

As an engineer turned physician, I’m driven by solving complex problems - few are as urgent as developing new treatments for mental health disorders.

Listen to my convo with Brand Li here: open.spotify.com/episode/6axV...

Lando Norris via insta: "PAPAYA ON TOP"

| #F1 #McLaren

We’ve come full circle. Sickness and death - from milk specifically - in the 19th century was one of the single biggest drivers leading to the establishment of the FDA

Why inflammatory reductionism is a threat to psychiatry (and the rest of medicine) Thomas Pollak explores the emergence of a new worldview which attempts to explain all manner of ills as the result of inflammation or immune dysfunction. H

This essay has been long overdue. Chapeau to Tom Pollock for writing it.

academic.oup.com/brain/advanc...

Would love to be added! CEO at atai Life Sciences.

@daphnezohar.bsky.social, great to see you on BlueSky and to see you in person at CNS Summit!

‘We dodged a bullet’: Biotech and pharma react to selection of Marty Makary for FDA commissioner “We dodged a bullet”: Biotech and pharma react to selection of Marty Makary for FDA commissioner.

‘We dodged a bullet’: Biotech and pharma react to selection of Marty Makary for FDA commissioner
Many appear cautiously optimistic about Trump’s intended pick

www.statnews.com/2024/11/23/m...

Bluesky is the new destination for X/Twitter’s health and science community. Here's why #MedTwitter is migrating en masse from X to Bluesky, suddenly making it an essential hub for scientific discourse. Here's why.

STAT’s @katiepalmer.bsky.social documents whet feels very palpable to me: Science and med 🧬🧪twitter moving rapidly to Blue Sky social. Happy to see so many former connections here. www.statnews.com/2024/11/21/b...

Sigh

I’ve seen enough to make a call: Bluesky is going to be a legit competitor to Twitter.

Sweet.

If you're paying 100 million for Superbowl ads to convert people to Jesus instead of housing the homeless, you read the wrong book.

Boom.